Research Article

The association between the *miR-146a* rs2910164 C>G polymorphism and Kawasaki disease in a southern Chinese population

Li Zhang1,* , Jinxin Wang2,* , Di Che3,* , Yanfei Wang1, Xing Rong2, Lei Pi3, Yufen Xu3, Wei Li1, Ping Huang1, Maoping Chu2 and Xiaoqiong Gu3

1Department of Cardiology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China; 2Children’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou 325027, Zhejiang, China; 3Department of Clinical Lab and Biological Resource Bank, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China

*Correspondence: Xiaoqiong Gu (gxiaqiong@163.com) or Maoping Chu (chmping@hotmail.com)

miR-146a plays a critical role in innate immune and inflammatory responses. Kawasaki disease involves immune-mediated inflammatory responses, which leads to vascular endothelial injury. However, there has been no study on the association between the *miR-146a* rs2910164 C>G polymorphism and Kawasaki disease risk. We enrolled 532 Kawasaki disease patients and 623 healthy controls from southern Chinese population, and the *miR-146a* rs2910164 C>G polymorphism was genotyped by the TaqMan method. There was no evidence that this polymorphism was associated with Kawasaki disease. Stratified analysis also showed no significant association. The present study indicates that the *miR-146a* rs2910164 C>G polymorphism may not be associated with Kawasaki disease in the southern Chinese population. Larger multicenter studies are needed to confirm our conclusions.

Introduction

Kawasaki disease, a systemic syndrome, involves vasculitis associated with fever and primarily endangers young children (age less than 5 years) [1]. This disease has become the leading cause of acquired heart disease in children in developed countries [2]. The incidences are highest amongst the Asians and Pacific Islanders [3]. Epidemiological studies have shown a strong tendency to genetic predisposition in Kawasaki disease. The etiology of Kawasaki disease is not entirely clear. This disease is now known to be an immune-mediated inflammatory response, which leads to vascular endothelial injury [4]. Coronary lesions are the main complication of Kawasaki disease. Moreover, as the proportion of typical Kawasaki disease decreased and incomplete Kawasaki disease increased [5], the difficulty of diagnosis also increased.

miRNAs are 20–25 nts in length and are non-coding ssRNA molecules that regulate gene expression via mRNA. miRNAs play a role in tumorigenesis [6], diabetes [7], cardiac hypertrophy [8], and ischemic heart failure [9]. Previously, many miRNAs have been used as biomarkers for a variety of diseases, and some of these molecules have been identified as diagnostic biomarkers for Kawasaki disease, such as *miR-200c* and *miR-371-5p* [10]. We noted that *miR-146a* plays a pivotal role in innate immune [11,12] and inflammatory responses [13-15]. Innate immune and inflammatory responses are the basic pathogenesis of Kawasaki disease [16]. These findings prompted us to examine whether the *miR-146a* rs2910164 C>G polymorphism is associated with Kawasaki disease and whether the rs2910164 C>G polymorphism can be used as a potential risk factor or as a biomedical indicator. However, there was no previous research on the association between the *miR-146a* rs2910164 C>G polymorphism and Kawasaki disease; thus, we carried out the present study.
Table 1 Genotype distributions of the miR-146a rs2910164 C>G polymorphism and Kawasaki disease susceptibility

| Genotype | Cases (n=532) | Controls (n=616) | P* | Crude OR (95% CI) | P | Adjusted OR (95% CI)† | P† |
|----------|---------------|-----------------|----|-----------------|---|---------------------|----|
| rs2910164 (HWE = 0.902) | | | | | | | |
| CC       | 199 (37.41)   | 230 (37.34)     | 1.00 | 1.00          | | | |
| CG       | 258 (48.50)   | 294 (47.73)     | 1.03 (0.80–1.33) | 0.807 | 1.01 (0.79–1.30) | 0.924 |
| GG       | 75 (14.10)    | 92 (14.94)      | 0.96 (0.67–1.37) | 0.818 | 0.96 (0.66–1.36) | 0.763 |
| Additive | | | 0.917 | 0.98 (0.83–1.16) | 0.823 | 0.98 (0.83–1.16) | 0.834 |
| Dominant | 333 (62.59)   | 386 (62.66)     | 0.981 | 1.00 (0.79–1.27) | 0.981 | 1.00 (0.78–1.27) | 0.979 |
| Recessive| 457 (85.90)   | 524 (85.06)     | 0.688 | 0.94 (0.67–1.30) | 0.689 | 0.94 (0.68–1.31) | 0.712 |

* χ² test for genotype distributions between Kawasaki disease patients and controls.
† Adjusted for age and gender.
HWE: Hardy-Weinberg equilibrium.

Materials and methods
Study subjects
The present study included 532 children who were diagnosed with Kawasaki disease from the Guangzhou Women and Children’s Medical Center from January 2012 to December 2017 [17]. Diagnostic criteria referred to the 2004 American Heart Association recommendations [2], and 623 age- and gender-matched healthy children at the hospital in the same period for physical examination were also analyzed. Blood samples were provided by the Clinical Biological Resource Bank of the Guangzhou Women’s and Children’s Medical Center. Information on each case, such as age, gender, coronary artery lesion (CAL), and coronary artery aneurysm (CAA), were collected. CAL and CAA were also graded according to the 2004 American Heart Association recommendations. The present study obtained the consent of the participants’ parents or guardians and was approved by the Guangzhou Women and Children’s Medical Center Medical Ethics Committee (ethics number: 2014073009).

Genotyping
We extracted the DNA from the blood samples. The extracted DNA was placed in a −80°C refrigerator until use. For genotyping of the rs2910164 C>G polymorphism, we used ABI Q6 instrument (Applied Biosystems) and TaqMan assays [18–20]. The genotypes of cases and controls were determined during this process. For quality control, each 384-well plate contained eight samples without DNA but with the same amount of distilled water.

Statistical analysis
The differences in the distribution of data of children with Kawasaki disease and healthy controls were assessed by the χ² test. Odds ratios (ORs) and 95% confidence intervals (CIs) of homozygotes (GG compared with CC), heterozygotes (CG compared with CC), a recessive model (GG compared with CC + CG), and a dominant model (CC + CG compared with CC) were used to assess the association between the miR-146a rs2910164 C>G polymorphism and Kawasaki disease. Univariate and multivariate regression models were used to calculate the OR values. Additionally, the association between the rs2910164 C>G polymorphism and Kawasaki disease was stratified by gender, age, CAL, and CAA. The statistics were performed by SAS software (version 9.4, SAS Institute, Cary, NC, U.S.A.).

Results
Demographic characteristics
The demographic characteristics of the study subjects are shown in Supplementary Table S1. The average age of onset of the cases was 28.39 ± 24.68 months, 68.61% were male, the male to female ratio was 2.19:1, CAL accounted for 31.58%, and CAA accounted for 9.59%. The average age of the controls was 28.48 ± 25.33 months, and 64.53% were male (P=0.143). There were no significant differences in age and gender between Kawasaki disease patients and controls (P=0.602). Gender, age, and coronary artery outcomes were adjusted for further analysis.

Genotype distributions
The rs2910164 allele frequencies in the case group and control group are shown in Table 1, as well as the association between the rs2910164 C>G polymorphism and Kawasaki disease risk. The data showed that rs2910164 C>G was
Table 2 Stratification analysis for the association between the miR-146a rs2910164 C>G polymorphism and Kawasaki disease susceptibility

| Variables | CC Cases/controls | CG/GG Cases/controls | Crude OR (95% CI) | P | Adjusted OR* (95% CI) | P* |
|-----------|------------------|---------------------|-------------------|---|----------------------|----|
| Age, months | | | | | | |
| <12 | 46/66 | 91/98 | 1.33 (0.83–2.14) | 0.234 | 1.32 (0.82–2.13) | 0.254 |
| 12–60 | 133/144 | 218/247 | 0.96 (0.71–1.29) | 0.765 | 0.96 (0.71–1.29) | 0.765 |
| >60 | 20/20 | 24/41 | 0.59 (0.26–1.30) | 0.189 | 0.55 (0.24–1.25) | 0.154 |
| Gender | | | | | | |
| Females | 62/84 | 105/137 | 1.04 (0.69–1.57) | 0.859 | 0.99 (0.65–1.52) | 0.978 |
| Males | 137/146 | 228/249 | 0.98 (0.73–1.31) | 0.871 | 0.97 (0.72–1.31) | 0.856 |
| CAA | | | | | | |
| CAA | 17/230 | 34/386 | 1.19 (0.65–2.18) | 0.570 | 1.18 (0.65–2.17) | 0.585 |
| NCAA | 182/230 | 299/386 | 0.98 (0.77–1.25) | 0.865 | 0.98 (0.77–1.25) | 0.873 |
| CAL | | | | | | |
| CAL | 57/230 | 111/386 | 1.16 (0.81–1.66) | 0.416 | 1.16 (0.81–1.67) | 0.414 |
| NCAL | 142/230 | 222/386 | 0.93 (0.71–1.22) | 0.601 | 0.93 (0.71–1.22) | 0.597 |

*Adjusted for age and gender.

not significantly associated with Kawasaki disease compared with the controls (CG compared with CC: OR = 1.01, 95% CI = 0.79–1.30; GG compared with CC: OR = 0.95, 95% CI = 0.66–1.36; GG compared with CC + CG: OR = 0.94, 95% CI = 0.68–1.31, CC + CG compared with CC: OR = 1.00, 95% CI = 0.78–1.27).

Stratification analysis

The stratification analyses were based on gender, age, and coronary artery abnormality. It was indicated that the rs2910164 C>G polymorphism had no significant association with Kawasaki disease risk in different age groups, between males and females, CAA and NCAA, CAL and NCAL (Table 2).

Discussion

Genetic susceptibility has become a concern for Kawasaki disease research, but few studies have examined the association of miRNA polymorphisms with Kawasaki disease. He et al. [21] reported that miR-483 contributes to coronary artery abnormalities in Kawasaki disease; Shimizu et al. [22] reported that miR-145 affects patients with Kawasaki by the TGF-β pathway; and Yun et al. [10] reported that miR-200c and miR-371-5p were involved in Kawasaki disease by regulating the inflammatory response.

By the means of promoter analysis, miR-146a was found to be an NF-kB-dependent gene and base pairs with sequences in the 3′-UTRs of the TNF receptor-associated factor 6 and IL-1 receptor-associated kinase 1 genes [12,13], which played an important role in Kawasaki disease-induced vasculitis [23,24]. miR-146a expression provided a novel mechanism for the negative regulation of severe inflammation [12,13,25], and miR-146a was involved in vascular endothelial cell senescence through NADPH oxidase-4 (NOX4) [26]. Thus, we wondered whether there was an association between miR-146a and Kawasaki disease. Furthermore, miR-146a rs2910164 C>G was found to increase the HBV-related hepatocellular carcinoma risk especially in the Chinese population, and meta-analysis results suggested that the rs2910164 C>G polymorphism was associated with increased breast cancer risk [27,28]. Therefore, we carried out the present study with a relatively large sample size, including 532 cases and 623 healthy children from southern Chinese population, and miR-146a was selected as the study subject.

The present study showed that miR-146a rs2910164 C>G was not associated with Kawasaki disease and was not related to other parameters such as gender, age, CAL, and CAA. Kawasaki disease is more prevalent in males and young children, less than 5 years old. The results of this experiment showed that the rates of the miR-146a rs2910164 C>G polymorphism in different gender groups and age groups had no difference. The major complications in Kawasaki disease are CALs and CAs. In stratified analysis, there were also no significant correlations between the miR-146a rs2910164 C>G polymorphism and CAL or CAA risk in Kawasaki disease. Our current study showed that the miR-146a rs2910164 C>G polymorphism may not be suitable as a biomarker for the diagnosis or prognosis of Kawasaki disease.
The current study has some limitations. First, the analysis of Kawasaki disease included gender, age, CAL, and CAA, but other factors such as family history and birth history [5], were not taken into account in the stratification analysis due to the lack of information. These factors may affect the results if the information was available. Second, the study was limited to southern Chinese population, and cases and controls from other ethnic groups were not assessed. Given the vast differences in the incidence of Kawasaki disease amongst different races, the distribution and the function of miR-146a in various populations require further study.

In conclusion, we carried out a case-control study with a relatively large sample size with 532 cases and 623 healthy controls from southern Chinese population. The association between the miR-146a rs2910164 C>G polymorphism and Kawasaki disease, as well as other parameters such as coronary artery complications, were not significant. Larger multicenter studies are needed.

Acknowledgements
We thank the Clinical Biological Resource Bank of Guangzhou Women and Children’s Medical Center for providing all the clinical samples.

Funding
This work was supported by the Guangdong Natural Science Fund, China [grant number 2016A030313836]; the Guangdong Science and Technology Project, China [grant number 2014A020212012]; the Guangzhou Medical and Health Technology Projects, China [grant number 2017A011260]; and the Guangzhou Science and Technology Program Project, China [grant number 201510010159 and 201510010287].

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Author contribution
All authors contributed significantly to this work. L.Z., D.C., Y.W., X.R., L.P., Y.X., W.L., and P.H. performed the research study and collected the samples and data. J.W. and D.C. analyzed the data. M.C. and X.G. designed the research study. J.W., M.C., and X.G. wrote the paper. J.W. and X.G. prepared all the tables. All authors reviewed the manuscript. In addition, all authors have read and approved the manuscript.

Abbreviations
CAA, coronary artery aneurysm; CAL, coronary artery lesion; CI, confidence interval; HBV, hepatitis B virus; IL-1, interleukin-1; NCAA, non-coronary artery aneurysm; NCAL, non-coronary artery lesion; OR, odds ratio; TGF-β, transforming growth factor-β; TNF, tumor necrosis factor.

References
1. Newburger, J.W., Takahashi, M. and Burns, J.C. (2016) Kawasaki disease. J. Am. Coll. Cardiol. 67, 1738–1749, https://doi.org/10.1016/j.jacc.2015.12.073
2. Newburger, J.W., Takahashi, M., Gerber, M.A., Gewitz, M.H., Tani, L.Y. et al. (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110, 2747–2771, https://doi.org/10.1161/01.CIR.0000145143.19711.78
3. McCrindle, B.W., Rowley, A.H., Newburger, J.W., Burns, J.C., Bolger, A.F. et al. (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135, e927–e999, https://doi.org/10.1161/CIR.0000000000004894
4. Yeung, R.S. (2010) Kawasaki disease: update on pathogenesis. Curr. Opin. Rheumatol. 22, 551–560, https://doi.org/10.1097/BOR.0b013e32833cf051
5. Nakamura, Y., Yashiro, M., Uehara, R., Sadakane, A., Tsuboi, S. et al. (2012) Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J. Epidemiol. 22, 216–221, https://doi.org/10.2188/jea.JE20110126
6. Ambros, V. (2004) The functions of animal microRNAs. Nature 431, 350–355, https://doi.org/10.1038/nature002871
7. Poy, M.M., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X. et al. (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432, 226–230, https://doi.org/10.1038/nature03076
8. Care, A., Catalucci, D., Felitti, F., Bonci, D., Addario, A. et al. (2007) MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13, 613–618, https://doi.org/10.1038/nm1582
9. Silvestri, P., Di Russo, C., Rigattieri, S., Fedele, S., Todaro, D. et al. (2009) MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat. Cardiovasc. Drug Discov. 4, 109–118, https://doi.org/10.2174/157489009788452977
